Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SJ 733

Next Previous
Drug Profile

SJ 733

Alternative Names: (+)-SJ 000557733; SJ-557733; SJ-733

Latest Information Update: 28 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Developer Eisai Co Ltd; Medicines for Malaria Venture; QIMR Berghofer Medical Research Institute; St. Jude Childrens Research Hospital; University of Kentucky
  • Class Amides; Antimalarials; Fluorobenzenes; Isoquinolines; Nitriles; Pyridines; Small molecules
  • Mechanism of Action PfATP4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Vivax malaria
  • No development reported Malaria

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for phase-I development in Malaria(In volunteers) in Australia (PO)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Malaria(In volunteers) in USA (PO)
  • 15 Apr 2022 University of Kentucky and Eisai completes a phase II trial in Vivax malaria (Combination therapy, Monotherapy, In adults, In the elderly) in Peru (PO) (NCT04709692)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top